Please login to the form below

Not currently logged in
Email:
Password:

vedolizumab

This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.

Biologics set to revolutionise the gastrointestinal market

Biologics set to revolutionise the gastrointestinal market

Also contributing to the predicted market growth are recent product approvals such as Takeda's Takecab (vonoprazan) for gastroesophageal reflux disease, and Entvio (vedolizumab) for IBD.

Latest news

More from news
Approximately 8 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Navigating the social media waters in healthcare
...
What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?
Paul Midgley, Director of NHS Insight at Wilmington Healthcare, explains how pharma should tailor its approach...
robot
AI’s potential in the pharma life cycle
At a time that the future of life sciences is being hotly debated, the opportunity for the industry to refine and expand its role is an important one to take...

Infographics